Accelerate the generation and validation of new immunotherapy antibodies against cancers and inflammatory diseases

Founding member of the Marseille Immunopole cluster, Mi-mAbs is  an innovative immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory diseases.
At the interface of "therapeutic targets discoverers” from research and developers of the biopharmaceutical industry, it helps to make the Marseille metropolis a world leader in research and development of immune-based therapies, and first and foremost for immunotherapy antibodies.

Open to the best targets of academic and industrial research, MI-mAbs determines their expression profile in humans and mice, generates antibodies to manipulate them, characterizes the mechanisms of action of these antibodies and validates their efficacy and their safety on in vivo models of human disease and in vitro, on human biological samples.

In establishing the first proof of concept of these new immunotherapy antibodies, Mi-mAbs thus helps biopharmaceutical companies responsible for converting them into drugs to immediately focus their efforts on the most promising antibody candidates.

Prize-Winner of the program « Investments for the Future » 2011 in the "preindustrial demonstrators" category, MI-mAbs was established by Aix-Marseille Université (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institute Paoli-Calmettes (IPC), 3 of their research centers (the Centre d’Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Centre for Immunophenomics), the European leader in immuno-oncology, Innate Pharma and Sanofi, one of the world leaders in health.

MI-mAbs is located in a building of 1000m2, renovated by Aix-Marseille Provence Métropole, at the heart of Marseille Immunopôle, on the science and technological park of Marseille-Luminy.